These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 25213022)
1. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers. Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663 [TBL] [Abstract][Full Text] [Related]
3. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073 [TBL] [Abstract][Full Text] [Related]
5. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297 [TBL] [Abstract][Full Text] [Related]
6. RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance. Abdel-Rahman MA; Mahfouz M; Habashy HO Diagn Pathol; 2022 Jan; 17(1):1. PubMed ID: 34986845 [TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma. Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839 [TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Liu X; Zhang H; Lai L; Wang X; Loera S; Xue L; He H; Zhang K; Hu S; Huang Y; Nelson RA; Zhou B; Zhou L; Chu P; Zhang S; Zheng S; Yen Y Clin Sci (Lond); 2013 May; 124(9):567-78. PubMed ID: 23113760 [TBL] [Abstract][Full Text] [Related]
9. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer. Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382 [TBL] [Abstract][Full Text] [Related]
10. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Putluri N; Maity S; Kommagani R; Creighton CJ; Putluri V; Chen F; Nanda S; Bhowmik SK; Terunuma A; Dorsey T; Nardone A; Fu X; Shaw C; Sarkar TR; Schiff R; Lydon JP; O'Malley BW; Ambs S; Das GM; Michailidis G; Sreekumar A Neoplasia; 2014 May; 16(5):390-402. PubMed ID: 25016594 [TBL] [Abstract][Full Text] [Related]
11. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2. Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer. Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266 [TBL] [Abstract][Full Text] [Related]
13. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689 [TBL] [Abstract][Full Text] [Related]
14. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605 [TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma. Das B; Jain N; Mallick B Gene; 2022 Jan; 808():145988. PubMed ID: 34624457 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer. Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136 [TBL] [Abstract][Full Text] [Related]
17. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer. Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF Dis Markers; 2015; 2015():302649. PubMed ID: 26663950 [TBL] [Abstract][Full Text] [Related]
18. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754 [TBL] [Abstract][Full Text] [Related]
19. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899 [TBL] [Abstract][Full Text] [Related]
20. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer. Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]